Racial/Ethnic Parity in Low-Dose Aspirin for Women With History of Preeclampsia After National Recommendations [26C

Abstract

INTRODUCTION: Hypertensive disorders of pregnancy are associated with severe maternal morbidity and maternal mortality, particularly for non-white women. Our goal was to investigate the effect of race/ethnicity on low-dose aspirin use following release of national guidelines for prevention of preeclampsia. METHODS: This is a retrospective cohort study of women with a history of preeclampsia delivering in a single institution from 1/1/2015 to 9/30/2017 following publication of “Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: U.S. Preventative Services Task Force Recommendation Statement.” Billing codes were used to identify women with indications for low-dose aspirin during pregnancy. A history of preeclampsia was then confirmed by chart abstraction. Race/Ethnicity as documented in the medical record and reported use of low-dose aspirin was abstracted from the electronic medical record. A one-way ANOVA was used to compare aspirin use in women identified as “white,” “Hispanic,” “black or African American,” and “other.” RESULTS: We identified 110 women eligible to receive low-dose aspirin based on a history of preeclampsia. 25.5% (n=28) of women with a history of preeclampsia were documented as receiving low-dose aspirin during the study period. 39.1% of women were identified as “white” (n=43), 30.9% (n=30.9) were identified as “Hispanic or Latina” (n=34), 21.8% were identified as “black or African American,” and 8.2% were identified as “Other” (n=9). There was no statistically significant difference in low-dose aspirin by race/ethnicity (P=.52). CONCLUSION: Immediately following recommendations for low-dose aspirin use for prevention of preeclampsia, aspirin use did not vary by reported race/ethnicity.